Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Given the challenges of recruiting patients for palliative care studies, Eric Roeland, MD, of the University of California, San Diego, discusses a way to increase the participation of those with cachexia, with the hope of improving treatment (Abstract 67).
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the ways in which a dedicated palliative radiation consult service can improve the quality of palliative cancer care (Abstract 110).
Amelie Harle, MD, of the Christie NHS Foundation Trust, discusses a clinical trial––the first of its kind—designed to assess the efficacy of an antitussive in patients with lung cancer (Abstract 2).
Kathleen Foley, MD, of Memorial Sloan Kettering Cancer Center, discusses the challenges of integrating palliative care in areas without sufficient resources or health-care infrastructure.
Vicki Jackson, MD, MPH, of Massachusetts General Hospital, summarizes her keynote lecture (plenary talk).
